Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
Large Granular Lymphocyte Leukemia
DRUG: Siltuximab
Overall Response Rate, Overall response rate is defined as the rate of achieving best response of CR or PR, and will be summarized for participants who have received any dose of study drug, Up to 30 months
Complete Response Rate (CR), CR rate is defined as the percentage of patients achieving best response of CR., Up to 30 months|Time to Response (TTR), TTR is defined as time from first dose of study drug to time of meeting criteria for CR or PR, whichever comes first., Up to 30 months|Duration of Response (DOR), Duration of Response is defined as time from achieving either CR or PR, whichever comes first, to time of progression or starting another LGLL treatment, whichever comes first., Up to 30 months|Duration of Complete Response, Duration of CR is defined as time from achieving CR to time of progression or starting another LGLL treatment, whichever comes first., Up to 30 months|Time to Complete Response, Time to CR is defined as time from first dose of study drug to time of CR, Up to 30 months|Duration of Complete Response with Normalization of PB LGL Count, Rate of CR with normalization of PB LGL count is defined as meeting criteria for CR AND a normal PB LGL count ( \<400/mm³ CD3+CD57+ cells or \<650/mm³ CD8+ T cells in PB)., Up to 30 months|Progression Free Survival, PFS is defined as time from first dose of study drug to time of disease progression or starting another LGLL treatment, whichever comes first, Up to 30 months
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).